Published: December 2024 | Last updated: April 2026
Most people who arrive at a clinic worried about an STI are worried about the wrong infection first. They have read about HIV transmission and panicked, when statistically what they are most likely to have picked up is HPV or chlamydia. Those two behave nothing like HIV. Eight infections account for the overwhelming majority of new sexually transmitted cases in the United States, and each one spreads differently, presents differently, and needs a different waiting period before a test can reliably detect it. If you do not know which infection has which window, your test result is partly luck of the draw. This guide walks through what each one is, how it actually moves between people, and what a sensible at-home or clinic testing plan looks like.
What are the most common STIs and how do they spread?
The eight infections that drive nearly all new US cases are HPV, chlamydia, gonorrhea, trichomoniasis, herpes (HSV-1 and HSV-2), syphilis, HIV, and hepatitis B and C. They transmit through five main routes: mucosal contact during penetrative sex, skin-to-skin contact, oral contact, blood-to-blood exposure (shared needles), and from a pregnant person to the baby. Most cases produce no early symptoms, which is why scheduled screening matters more than waiting for something to feel wrong.
The eight STIs behind most new infections in the United States
The US Centers for Disease Control and Prevention tracks several dozen sexually transmitted infections, but eight of them account for nearly all of the new diagnoses reported each year. It is worth understanding each one on its own terms before lumping them together under the STI umbrella, because their treatment, prognosis, and testability vary widely.
A quick disclosure: this article is published by stdrapidtestkits.com, which sells at-home rapid STI testing kits. Catalog mentions below describe what our kits cover; they are not clinical recommendations.
HPV (human papillomavirus)
The single most common STI in the United States. The CDC estimates that nearly all sexually active people will acquire HPV at some point in their lives if they are not vaccinated. Most infections clear on their own within two years without symptoms or treatment. A subset of high-risk strains can cause cervical, anal, throat, and penile cancers years later, which is why the HPV vaccine and routine cervical screening matter even for people with no symptoms. There is no FDA-approved at-home male HPV test, and the rapid HPV swab in our catalog is validated for vaginal self-collection only.
Chlamydia
The most commonly reported bacterial STI. CDC chlamydia surveillance data records approximately 1.6 million reported cases in the most recent reporting year, and the true number including unreported asymptomatic infections is estimated several times higher. Most genital chlamydia infections cause no symptoms in the first weeks. When symptoms do appear, they tend to be unusual discharge, burning during urination, or pelvic pain. Untreated chlamydia is a leading preventable cause of pelvic inflammatory disease and tubal-factor infertility in women, and it can cause epididymitis in men. A standard course of doxycycline cures it.
Gonorrhea
Often called "the clap." CDC gonorrhea surveillance reports on the order of 600,000 cases per year in the US. Like chlamydia it can infect the urethra, cervix, rectum, and throat, and like chlamydia it is frequently silent. Gonorrhea is the bigger antibiotic-resistance worry of the two: the CDC currently recommends a single 500 mg dose of ceftriaxone, the last broadly reliable first-line treatment after the bacterium developed resistance to fluoroquinolones, azithromycin, and earlier cephalosporins. Annual screening is recommended for sexually active women under 25 and for men who have sex with men.
Trichomoniasis
A parasitic infection caused by Trichomonas vaginalis. The CDC estimates around 2 million prevalent cases in the US at any given time. Roughly 70 percent of infected people have no symptoms. When symptoms appear they include itching, burning, frothy yellow-green discharge, and a strong odor. A single dose of metronidazole or tinidazole clears it. Our at-home trich kit is validated for vaginal self-swab only; male partners needing a test should see a clinic for urethral testing.
Genital herpes (HSV-1 and HSV-2)
Two related viruses cause genital herpes. HSV-1 is historically associated with cold sores around the mouth but is an increasing share of new genital herpes cases through oral-to-genital contact. HSV-2 is the classic genital strain. Both spread through skin-to-skin contact with an active outbreak or, importantly, with skin that is shedding virus asymptomatically. Once acquired, the virus stays in nerve tissue for life. Antivirals like valacyclovir reduce outbreak frequency and lower transmission risk to partners but do not eradicate the infection. Most rapid blood tests on the market detect HSV-2 antibodies; a separate kit is needed for HSV-1.
Syphilis
A bacterial infection that has surged dramatically in the past decade in the US, including a steep rise in congenital syphilis cases reported to the CDC. Syphilis progresses through stages: a single painless ulcer (chancre) at the site of infection, then weeks-to-months later a body-wide rash, then a long latent period, then potential damage to the heart, brain, and nerves. It is highly curable with penicillin at any stage, but the early presentations are easy to miss because the chancre does not hurt and resolves on its own.
HIV
Around 30,000 to 40,000 new HIV diagnoses per year in the US, per CDC HIV surveillance. HIV transmits through specific bodily fluids: blood, semen, vaginal and rectal fluids, and breast milk. The most common routes are anal or vaginal sex without a condom or PrEP, and shared injection equipment. Modern antiretroviral therapy can suppress the virus to undetectable levels, at which point it is also untransmittable to sexual partners (the U=U principle established by NIH-funded studies). Pre-exposure prophylaxis (PrEP) is highly effective for HIV-negative people at higher risk. Detection windows depend on the test type, which we cover in the section below.
Hepatitis B and Hepatitis C
Often grouped under sexual-health testing because both can transmit through sex (especially hepatitis B) and through shared injection equipment. Per CDC guidance, hepatitis B is preventable with a vaccine that has been on the routine childhood schedule for decades. Hepatitis C is curable in most cases with 8 to 12 weeks of direct-acting antivirals, but the infection is frequently silent for years until liver damage shows up on routine bloodwork. The CDC now recommends at least one hepatitis C screening test for every adult.
| Infection | Type | Curable? | Vaccine available? | At-home test in our catalog |
|---|---|---|---|---|
| HPV | Virus | Most clear on their own; persistent strains need monitoring | Yes (Gardasil 9) | Vaginal swab (women only) |
| Chlamydia | Bacterium | Yes (doxycycline) | No | Vaginal or penile swab |
| Gonorrhea | Bacterium | Yes (ceftriaxone, with resistance concerns) | No | Vaginal or penile swab |
| Trichomoniasis | Parasite | Yes (metronidazole) | No | Vaginal swab (women only) |
| HSV-1 and HSV-2 | Virus | No (suppressible with antivirals) | No | Fingerstick blood antibody |
| Syphilis | Bacterium | Yes (penicillin) | No | Fingerstick blood antibody |
| HIV | Virus | No (suppressible to undetectable with ART) | No (PrEP available for prevention) | Fingerstick blood antibody |
| Hepatitis B and C | Virus | B preventable with vaccine; C curable with antivirals | B yes; C no | Fingerstick blood antibody |
How each one spreads
Lumping all STIs under one label obscures one of the most important facts about them: the transmission routes are not interchangeable. A barrier method that works well for one infection may do little against another. Five main routes account for the overwhelming majority of new cases.
Mucosal contact during penetrative sex
Vaginal and anal intercourse expose mucosal surfaces (the soft tissue lining the genital tract and rectum) to fluids and friction. This is the highest-yield route for chlamydia, gonorrhea, trichomoniasis, HIV, and hepatitis B. Receptive anal sex carries the highest per-act HIV risk because rectal mucosa is thinner and more easily disrupted than vaginal mucosa, per CDC guidance on HIV transmission risk.
Skin-to-skin contact
Several STIs do not require fluid exchange. HPV, herpes (HSV-1 and HSV-2), and syphilis can transmit through contact with skin or mucous membranes carrying the virus or bacterium. This is why condoms reduce but do not eliminate the risk for these three: a condom covers the penis, but the infectious surface (a herpes outbreak on the upper thigh, an HPV-positive area on the vulva, a syphilis chancre on the scrotum) may extend beyond what the condom covers.
Oral contact
Oral sex can transmit gonorrhea, chlamydia, syphilis, herpes (most commonly HSV-1), and rarely HIV. Throat (pharyngeal) gonorrhea is often asymptomatic and is increasingly recognized as an important reservoir for antibiotic-resistant strains. The at-home rapid kits in our catalog are validated for genital sample sites; if you have an oral exposure concern, a clinic-administered pharyngeal swab is the appropriate test.
Bloodstream exposure
Sharing injection equipment, accidental needlestick injuries in healthcare settings, and (rarely now in the US, due to rigorous donor screening) blood transfusion can transmit HIV, hepatitis B, and hepatitis C. Tattoos and piercings done with reused or improperly sterilized equipment are a small but real route for hepatitis B and C.
Vertical (parent-to-child)
Several STIs can pass from a pregnant person to the baby during pregnancy, delivery, or breastfeeding. Syphilis, HIV, hepatitis B, herpes, and chlamydia are the major ones. Standard prenatal care in the US includes routine first-trimester screening for syphilis, HIV, and hepatitis B for exactly this reason: most cases caught early can be prevented from passing to the baby with appropriate treatment.
Why most STIs feel like nothing at first
This is the single biggest reason routine screening matters. The majority of chlamydia, gonorrhea, trichomoniasis, HPV, herpes, and early-stage syphilis cases produce either no symptoms at all or symptoms so mild they get attributed to something else. People assume the discharge is a normal hormonal shift, the burning is a urinary tract infection, the rash is heat irritation. By the time something obvious appears, weeks or months may have passed and the infection may already have been transmitted to a partner.
Three patterns explain most of the silent-infection problem.
First, the infection can establish itself in tissues with limited sensory innervation. The cervix and the upper rectum have very few pain receptors, so a chlamydia or gonorrhea colony there can grow undetected for weeks.
Second, the host immune system can suppress visible symptoms without clearing the pathogen. Latent syphilis is the classic example: after the chancre and the secondary rash heal on their own, the bacterium continues to live in the body for years before causing damage to the cardiovascular or nervous system.
Third, viral STIs like HSV and HPV produce symptoms only intermittently or not at all. HSV sheds infectious virus on days when there is no visible outbreak (called asymptomatic shedding), which is responsible for a substantial portion of new herpes infections from partners who genuinely did not know they had the virus.
The practical takeaway: if you have had an unprotected exposure or a new partner, the absence of symptoms is not reassurance. For most of the common STIs, no-symptoms is the most common presentation.
A chlamydia or gonorrhea infection that produces no symptoms in you can still be transmitted to a partner. Per <a href="https://www.cdc.gov/herpes/" target="_blank" rel="noopener">CDC guidance on genital herpes</a>, asymptomatic shedding accounts for a substantial share of new HSV-2 transmissions, and HIV is most transmissible during the acute infection window when symptoms (if any) feel like a brief flu and are easily missed. The only way to interrupt silent transmission chains is scheduled screening of sexually active people, not symptom-driven testing.
Prevention methods ranked by impact
Some prevention measures cut transmission risk by 90 percent or more. Others cut it by maybe 30 percent. The interventions that move the needle most, ranked roughly by impact:
Vaccination where it exists
Two STIs have effective vaccines. HPV vaccine (Gardasil 9) covers nine of the highest-risk strains. The CDC recommends routine HPV vaccination starting at age 11 or 12, catch-up vaccination through age 26, and shared clinical decision-making for adults aged 27 to 45. Hepatitis B vaccination is on the routine childhood schedule and is also recommended for unvaccinated adults at risk.
PrEP for HIV
Daily oral PrEP (tenofovir-based regimens) reduces the risk of HIV acquisition through sexual exposure by more than 99 percent when taken consistently, per CDC PrEP guidance. A long-acting injectable PrEP (cabotegravir) given every two months is also FDA-approved. PrEP does not protect against any other STI, so condoms remain part of a layered strategy.
Condoms
Latex or polyurethane condoms used consistently and correctly substantially reduce the risk of fluid-transmitted STIs (HIV, gonorrhea, chlamydia, hepatitis B) and modestly reduce the risk of skin-to-skin STIs (herpes, HPV, syphilis). Internal condoms (formerly called female condoms) work similarly. No barrier method protects against an outbreak that extends beyond the area the condom covers.
Routine screening
Screening before symptoms appear is the only way to catch silent infections before they cause complications or transmit to a partner. The CDC recommends at least annual chlamydia and gonorrhea screening for all sexually active women under 25 and for men who have sex with men, hepatitis C screening at least once for every adult, and HIV screening at least once between ages 13 and 64. People with multiple partners or other risk factors should screen more often.
| Prevention method | Best against | Less effective against |
|---|---|---|
| HPV vaccine (Gardasil 9) | Nine high-risk HPV strains, including those that cause most cervical cancers | HPV strains not in the vaccine; other STIs entirely |
| Hepatitis B vaccine | Hepatitis B (very high efficacy after full series) | Hepatitis C (no vaccine exists); other STIs |
| Daily PrEP | HIV (>99% reduction with adherent use) | All other STIs |
| External condom (latex/polyurethane) | HIV, gonorrhea, chlamydia, trichomoniasis, hepatitis B | Skin-to-skin: herpes, HPV, syphilis (partial protection only) |
| Internal condom | Same as external condoms; covers more vulvar surface area | Skin-to-skin infections beyond the covered area |
| Annual screening | Catching silent chlamydia, gonorrhea, HIV, syphilis, hepatitis C early | Stopping a transmission that already happened before the screen |
When to test, and what window each one has
Every STI has a window period: the time between exposure and when a test can reliably detect it. Testing inside the window risks a false negative and a false sense of safety. The windows below come from CDC and FDA-approved test labelling and represent the time at which the relevant antibody, antigen, or DNA is detectable in most infected people. A small minority seroconvert later than the typical window, which is why a definitive all-clear point is usually given alongside the typical detection time.
Lateral-flow rapid tests (the at-home format) generally need slightly more antigen or antibody to be present than laboratory NAAT or fourth-generation tests, so the at-home window is a few days later than the lab window for the same infection. The two formats are complementary: rapid lateral-flow is for fast at-home screening, and a positive result is worth confirming with a clinic NAAT before treatment.
| Infection | Lab test detects from | Definitive all-clear | At-home rapid format |
|---|---|---|---|
| Chlamydia | 1 to 2 weeks (NAAT) | 2 weeks | Lateral-flow swab from ~14 days |
| Gonorrhea | 5 to 7 days (NAAT) | 2 weeks | Lateral-flow swab from ~7 days |
| Syphilis | 3 to 6 weeks (blood antibody) | 12 weeks | Lateral-flow blood from ~3 to 6 weeks |
| HIV (4th-gen lab) | 18 to 45 days (Ag/Ab) | 45 days | Lateral-flow blood antibody only: ~23 to 90 days |
| Hepatitis B | 3 to 6 weeks (HBsAg) | 9 weeks | Lateral-flow blood from ~6 weeks |
| Hepatitis C | 8 to 11 weeks (Ab) | 6 months | Lateral-flow blood from ~8 to 11 weeks |
| HSV-2 (blood antibody) | 6 to 12 weeks | 16 weeks | Lateral-flow blood from ~6 to 12 weeks |
| Trichomoniasis | Days after symptoms (NAAT) | 1 to 2 weeks | Lateral-flow swab (women) at symptom onset |
| HPV | No antibody test in routine use; cervical sample only | Cervical screening on schedule | Lateral-flow swab (women) for high-risk HPV detection |
What an at-home rapid test can and cannot tell you
At-home rapid STI tests use lateral-flow strip technology, the same chemistry as a home pregnancy test. A sample (a self-collected vaginal or penile swab, or a fingerstick drop of blood) is applied to a cassette, and after 15 to 20 minutes a control line and a test line indicate the result. The cassette reads as positive, negative, or invalid (control line did not develop, meaning the test must be repeated).
What rapid lateral-flow does well: speed, privacy, no clinic visit, and a clear binary answer for the most common infections inside their validated window period. Sensitivity for the rapid kits in our catalog is in the mid-to-high 90s for tested-and-validated sample types, per the manufacturer specifications on each product page.
What rapid lateral-flow does not do: it is not a NAAT (nucleic acid amplification test), and it is not equivalent to a laboratory NAAT in analytical sensitivity. NAATs amplify the pathogen's DNA or RNA and can detect very small amounts of organism. Lateral-flow strips need more antigen or antibody to be present, which is why the rapid window is slightly later than the lab window. A positive rapid result is meaningful and worth confirming with a clinic-based NAAT before starting treatment. A negative rapid result inside the validated window is reassuring; a negative result before the window is not yet meaningful and should be repeated later.
The rapid kits are designed for screening and triage, complementary to laboratory testing rather than a replacement for it. If you have a result you do not understand, persistent symptoms despite a negative test, or a high-risk exposure within the past few days, see a clinician.
Sexually transmitted infections (STIs) are very common. Millions of new infections occur every year in the United States. STIs pass from one person to another through sexual activity including vaginal, oral, and anal sex. Many STIs do not cause any symptoms, so testing is the only way to know for sure if you have one.
Talking to a partner about testing
The most common reason people delay STI testing is the conversation they imagine having with a partner about it. The conversation is almost always less awkward than the imagined version, and the most useful framings keep it routine rather than turning the request into an accusation.
If a current or former partner needs to be notified after a positive result, most US health departments offer anonymous partner-notification services. The CDC also points to web-based notification tools that allow you to send an anonymous message with information about the infection and where to get tested. Notification matters because untreated partners reinfect, and untreated infections continue to spread silently into other relationships.
- The neutral checkup. "I am due for my routine sexual-health screening. Want to do it together?" Positions testing as self-care, like a dental cleaning, not as an accusation about anyone's behavior.
- The new-relationship script. "Before we stop using condoms, I would like us both to get tested." Widely accepted as a reasonable ask in any new sexual relationship and frames testing as a shared decision.
- The post-exposure script. "I had an exposure I want to test for; you might want to test too." Direct and factual, leaves blame out of it.
Frequently asked questions
- Can you have an STI without any symptoms at all?
- Yes, and it is the most common presentation for chlamydia, gonorrhea, trichomoniasis, HPV, and early syphilis. CDC surveillance estimates that the majority of all chlamydia and gonorrhea cases produce no symptoms in the first weeks. This is the entire reason routine screening is recommended even for people who feel completely fine.
- Are all STIs curable?
- Bacterial STIs (chlamydia, gonorrhea, syphilis) and the parasitic STI trichomoniasis are curable with a course of antibiotics. Hepatitis C is curable in most cases with 8 to 12 weeks of direct-acting antivirals. Hepatitis B is preventable with a vaccine and manageable with antivirals if acquired. The viral STIs HIV, HSV-1, and HSV-2 are not curable, but each has effective treatment that suppresses the virus and substantially reduces transmission risk. HPV usually clears on its own; some strains have lasting effects that need monitoring.
- How often should I test if I am sexually active?
- For most sexually active adults with a single long-term partner, an annual screening is reasonable. For sexually active women under 25, the CDC recommends annual chlamydia and gonorrhea screening. Men who have sex with men should screen at least annually for HIV, syphilis, chlamydia, and gonorrhea, and every 3 to 6 months if they have multiple partners. Anyone starting a new sexual relationship should consider testing before condoms come off.
- Can oral sex transmit STIs?
- Yes. Gonorrhea, chlamydia, syphilis, HSV-1 (and less commonly HSV-2), and rarely HIV all transmit through oral-genital contact. Throat gonorrhea is a particular concern: it usually causes no symptoms, which means people do not know to seek treatment, and it has become a key reservoir for the antibiotic-resistant strains driving treatment failure rates worldwide. The at-home rapid kits we sell use genital-site samples; for an oral exposure specifically, ask a clinic about a pharyngeal swab with PCR confirmation.
- Do condoms eliminate STI risk completely?
- They substantially reduce the risk of fluid-transmitted infections (HIV, gonorrhea, chlamydia, hepatitis B) when used consistently and correctly. They reduce the risk of skin-to-skin infections (HPV, herpes, syphilis) more modestly, because the infectious surface may extend beyond the area the condom covers. No barrier method is 100 percent.
- What is the most common STI in the United States?
- HPV by a wide margin. CDC surveillance suggests most sexually active adults will encounter at least one HPV strain in their lifetime, though the great majority of infections clear without symptoms or treatment. Among bacterial infections, chlamydia leads, followed by gonorrhea. The reported numbers always understate the real picture because asymptomatic cases rarely get diagnosed; surveillance counts captured infections, not the population-level prevalence.
- How soon after a possible exposure should I test?
- It depends on the infection. Bacterial STIs (chlamydia, gonorrhea) reach reliable detectability within 1 to 2 weeks. HIV is conservatively cleared by an antibody-only rapid test at 90 days, or by a fourth-generation lab test by about 45 days. Syphilis blood tests should be repeated at 6 weeks if the first test is negative within 3 weeks of exposure. Hepatitis C should be retested at 6 months for definitive clearance. Testing too early risks a false negative.
- Can STIs spread through sharing razors, towels, or toilet seats?
- Razors that have been in contact with infected blood are a possible (uncommon) transmission route for hepatitis B and C. Towels, toilet seats, swimming pools, and casual surface contact do not transmit STIs in any practical sense. The pathogens responsible for the major STIs do not survive long outside the body or in chlorinated environments.
- U.S. Centers for Disease Control and Prevention. About Sexually Transmitted Infections (STIs): general overview, transmission routes, asymptomatic shedding, and screening recommendations.
- U.S. Centers for Disease Control and Prevention. HIV: surveillance, transmission risk by exposure type, prevention (PrEP), and detection-window guidance for antibody and antigen-antibody tests.
- U.S. Centers for Disease Control and Prevention. About HPV: vaccination guidance, age recommendations, and the link to cervical and other anogenital cancers.
- U.S. Centers for Disease Control and Prevention. Chlamydia: prevalence, surveillance, symptom patterns, screening recommendations, and treatment.
- U.S. Centers for Disease Control and Prevention. Gonorrhea: prevalence, surveillance, antibiotic-resistance trends, and current first-line treatment recommendations.
- U.S. Centers for Disease Control and Prevention. About Syphilis: stages of infection, congenital syphilis surveillance, and treatment.
- U.S. Centers for Disease Control and Prevention. Viral Hepatitis: hepatitis B vaccination, hepatitis C screening recommendations, and direct-acting antiviral cure rates.
- U.S. Centers for Disease Control and Prevention. Genital Herpes (HSV-1 and HSV-2): transmission from partners without visible sores, asymptomatic shedding, and antiviral suppression.
- World Health Organization. Sexually transmitted infections (STIs) fact sheet: global incidence and the four curable infections (syphilis, gonorrhea, chlamydia, trichomoniasis).
